Half-Year 2022 Financial and Clinical Trials Update
Venclexta
Novel small molecule Bcl-2 selective inhibitor - multiple myeloma
Indication
Phase/study
# of patients
Design
Primary endpoint
Status
CT Identifier
Relapsed or refractory multiple myeloma (MM)
Roche
Phase I
N=117
"
Dose escalation cohort:
Venclexta dose escalation
"
▪ Safety expansion cohort (t11;14):
Venclexta expansion
Combination:
Venclexta plus dexamethasone
Phase Ib/II
N=120
■ Venclexta plus carfilzomib plus dexamethasone
in t(11;14) positive r/r MM
Phase III
CANOVA
N=244
■ Venclexta plus dexamethazone vs pomalidomide
plus dexamethasone in t(11;14) positive r/r MM
"
Safety and maximum tolerated dose
FPI Q4 2012
Data presented at ASCO 2015
Updated data presented at ASCO 2016 and ASH
2016
Data published in Blood 2017;130(22):2401-
2409 and Am J Hematol 2021 Apr 1;96(4):418-
427
NCT01794520
■ Safety, objective response rate,
Pharmacokinetics, Pharmacodynamics
"
FPI Q1 2017
Data published Blood Adv 2021 Oct
12;5(19):3748-3759
NCT02899052
Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute;
Bcl-2-B-cell lymphoma 2; MM-multiple myeloma; r/r-Relapsed or refractory; ASCO-American Society of Clinical Oncology; ASH-American Society of Hematology
■ Progression-free survival
☐
■ FPI Q4 2018
NCT03539744
97
97
OncologyView entire presentation